lonza to build new smallmolecule manufacturing plant in

Leave Comment

Lonza to build new small-molecule manufacturing plant in ...

Apr 23, 2021  Lonza AG (Basel, Switzerland) announced the construction of a new small molecule manufacturing complex at its Visp, Switzerland site. The new manufacturing complex will occupy an overall footprint of approximately 2,000 m 2 with six levels of manufacturing space. The complex will offer several opportunities for future expansions supporting the small molecules technologies offering,

Get price

Lonza to build mRNA and small-molecule plants in Visp

Apr 29, 2021  Separately, Lonza plans to spend $212 million on a small-molecule manufacturing complex at the Visp site. The 2,000 m 2 facility will support

Get price

Lonza to build new small-molecule manufacturing plant in ...

April 25, 2021. Chemical Value Chain. Lonza AG (Basel, Switzerland) announced the construction of a new small molecule manufacturing complex at its Visp, Switzerland site. The new manufacturing complex will occupy an overall footprint of approximately 2,000 m2 with six levels of manufacturing

Get price

Lonza unveils plan for $218M small-molecule manufacturing ...

Apr 23, 2021  Swiss CDMO Lonza, currently ramping up its COVID-19 vaccine manufacturing capabilities, unveiled plans to construct a small-molecule manufacturing complex in Visp, Switzerland, with the support of ...

Get price

News Lonza

Apr 23, 2021  Lonza Announces Construction of a New Small Molecule Manufacturing Complex in Visp. Lonza will invest CHF 200 million to construct a new manufacturing complex. The 2000 m2 complex will include a customer dedicated manufacturing line for antibody-drug conjugate payload molecules. The investment is supported by a long-term collaboration and ...

Get price

Lonza to build new small-molecule manufacturing plant in ...

Lonza AG (Basel, Switzerland) announced the construction of a new small molecule manufacturing complex at its Visp, Switzerland site. The new manufacturing complex will occupy an overall footprint of approximately 2,000 m2 with six levels of manufacturing space. The complex will offer several opportunities for future expansions supporting the small molecules technologies offering, which ...

Get price

Lonza Building New Swiss Plant, Expands Moderna COVID-19 ...

Lonza Building New Swiss Plant, Expands Moderna COVID-19 Manufacturing Deal. ... Group (Basel, Switzerland) has announced a series of major projects for its Visp facility in Switzerland, including a new $218 million small molecule manufacturing complex and separate plans to double the drug substance production for Moderna's (NASDAQ:MRNA ...

Get price

News Lonza

May 06, 2021  Lonza will invest approximately CHF 850 million to build two new state-of-the-art mammalian facilities and respond to customer demand regarding capacity, life cycle management and speed to market. A new large-scale facility with the latest manufacturing technology in Visp (CH), will expand capacity by six 20,000L bioreactors to meet increasing ...

Get price

Lonza plots $935M in capacity upgrades in Europe and U.S ...

May 06, 2021  Lonza has designs on an 850 million Swiss franc ($935 million) expansion at sites in Switzerland and New Hampshire. The CDMO plans to stand up two new mammalian manufacturing

Get price

Lonza Updates Plan for New Mammalian Biomanufacturing ...

Apr 07, 2020  Lonza is proceeding with plans for a new mammalian biologics development and manufacturing facility in Guangzhou, China. David Maier, Head of China Strategic Growth Projects, Mammalian Microbial Development Manufacturing, Lonza, outlined the details of the expansion and how it fits into the company’s overall biomanufacturing network at the DCAT Member Company

Get price

Lonza to expand manufacturing center in Nansha, China ...

Jun 28, 2021  Lonza AG (Basel, Switzerland) announced new investments in GMP laboratories and mid-scale manufacturing assets at its API manufacturing center in Nansha, China. The investments, totaling over CHF 20 million (around $22 million), will allow Lonza to provide a smoother transition from small-scale to large-scale manufacturing for customers while maintaining Lonza’s global quality and

Get price

Lonza to Expand API Manufacturing Facility ...

Jun 29, 2021  Integrated healthcare solutions supplier Lonza revealed plans Monday to invest CHF 20 million, or about $21.7 million, to expand the API development and manufacturing capabilities at its production site in Nansha, China.. The new mid-scale manufacturing assets at the Nansha site will support the transition of products under development to large-scale production.

Get price

Lonza Invests in Facility in China - genengnews

Jun 28, 2021  Lonza made new investments in GMP laboratories and mid-scale manufacturing assets at its API manufacturing center in Nansha, China. The investments, totaling over CHF 20

Get price

History Lonza

Lonza announced the construction of two new customer-dedicated conjugation suites for the commercialization of ADC in Ibex ® Dedicate, Visp (CH). 2021. Lonza was recognized by Ethisphere ® as one of the world's most ethical companies in 2021. Lonza announced the construction of a new small molecule manufacturing complex at its Visp (CH) site.

Get price

Small-Molecule Businesses - Annual Report 2018 - Lonza

Lonza added two new manufacturing suites at the Visp site for the manufacture of antibody drug conjugate (ADC) payloads, based on a tailored business agreement with a major biopharmaceutical partner. The new suites enable handling of a variety of highly potent products with occupational exposure levels down to 1ng/m 3 and thereby strengthen the overall bioconjugation capabilities of Lonza in Visp.

Get price

API Clinical Trial Material Development Services Lonza

Flexible API clinical trial material development and cGMP assets to support your chemical synthesis from concept to commercial . As part of our comprehensive product development for drug substances and intermediates, we provide phase-appropriate clinical trial material for feasibility studies, early and late phase clinical trials.

Get price

Building Products - Lonza

Lonza offers a wide range of active chemistries and delivery forms that can be formulated in many different ways to meet our customers’ needs. We specialize in creating products that are designed to provide protection against unwanted microorganisms. Our Building Products portfolio includes specialty biocides used for: In-can preservation.

Get price

Lonza Inaugurates New Plant for ADC Payload Manufacturing

Nov 06, 2020  Lonza Inaugurates New Plant for ADC Payload Manufacturing. 06.11.2020 Editor: Ahlam Rais. Launched virtually, the new facility located at the Visp site in Switzerland will be responsible for manufacturing antibody-drug conjugate drug-linkers. The plant will also strengthen the overall bioconjugation capabilities of the firm in the region.

Get price

Lonza to build plant for Sanofi - CEN

Mar 03, 2017  Lonza to build plant for Sanofi. A purification vessel at Lonza’s Portsmouth facility. Lonza and Sanofi have signed a supply agreement under which the Swiss chemical maker will operate a

Get price

LONN.S - Lonza Group AG Profile Reuters

Lonza Group AG (Lonza) is a Switzerland-based holding company and a supplier to the pharmaceutical, healthcare and life science industries. The Company's offerings include custom development and ...

Get price

Construction and Start-Up Costs for Biomanufacturing Plants

Feb 01, 2008  Non-GMP plants have between 40% and 60% of manufacturing area and a minimum of support (about 20% of soft cost). Time from construction to start-up would be 18–36 months for a biopharmaceutical plant and 6–12 months for a non-GMP plant.

Get price

Sanofi to bulldoze small-molecule plant it never used ...

May 16, 2017  Sanofi is taking that process a couple of steps further. It will demolish a plant it spent about $118 million to build and never even used. A Sanofi spokesperson confirmed Monday that

Get price

Lonza Announces Construction of a New Small Molecule ...

Apr 26, 2021  Basel, Switzerland, 23 April 2021 – Lonza, a CDMO partner to the biopharma industry, today announced the construction of a new small molecule manufacturing complex at its Visp (CH) site. The new manufacturing complex will occupy an overall footprint of approximately 2000 m2 with six levels of manufacturing space.

Get price

Lonza adds on small molecule facility at Visp site, adding ...

Apr 29, 2021  Lonza adds on small molecule facility at Visp site, adding new weight to its expansion plans on the back of a big year ... Moderna strikes a deal with Canada to build an mRNA manufacturing

Get price

Lonza to Expand API Manufacturing Facility in China ...

Lonza has announced new investments in GMP laboratories and mid-scale manufacturing assets at its API manufacturing center in Nansha, China. The investments will allow Lonza to provide a smoother transition from small-scale to large-scale manufacturing for customers, while maintaining Lonza’s global quality and regulatory standards. The expansion will include six 1,000litres small molecule ...

Get price

Lonza to Expand API Manufacturing Facility ...

Jun 29, 2021  Integrated healthcare solutions supplier Lonza revealed plans Monday to invest CHF 20 million, or about $21.7 million, to expand the API development and manufacturing capabilities at its production site in Nansha, China.. The new mid-scale manufacturing assets at the Nansha site will support the transition of products under development to large-scale production.

Get price

Lonza to build plant for Sanofi - CEN

Mar 03, 2017  Lonza to build plant for Sanofi. A purification vessel at Lonza’s Portsmouth facility. Lonza and Sanofi have signed a supply agreement under which the Swiss chemical maker will operate a

Get price

Biotech firms on the shoulders of giants

Jun 27, 2021  In December, the company entered an agreement with the giant contract manufacturer Lonza, which will build a dedicated plant for voclosporin in its small-molecule

Get price

API Research Development Chemical Process ... - Lonza

We offer a broad spectrum of research and development services for small molecule APIs using state-of-the-art chemical technologies. To achieve robust and efficient process qualification for scale-up, our API development process utilizes modern tools such as automated workstations, statistical software, and reaction calorimetry.

Get price

Chemical Custom Manufacturing - Lonza

Lonza has extensive experience in chemical custom synthesis, and we offer customers the benefit of a professional RD staff, high quality work, and an excellent customer service. Basic intermediates for the Agrochemical and other industries are produced in continuous, world-class production plants in the heart of Europe to guarantee quality and ...

Get price

Moderna to build mRNA production plant in Canada within ...

2 天前  Canada has also promised $126 million for a new National Research Council to build a biologics production plant in Montreal, that is set to make the Novavax vaccine, once it is approved. Canada also promised more than $400 million to help Sanofi complete a $925-million expansion of its vaccine production plant in Toronto.

Get price

Construction and Start-Up Costs for Biomanufacturing Plants

Feb 01, 2008  Non-GMP plants have between 40% and 60% of manufacturing area and a minimum of support (about 20% of soft cost). Time from construction to start-up would be 18–36 months for a biopharmaceutical plant and 6–12 months for a non-GMP plant.

Get price

Small Molecule API Development Manufacturing CordenPharma

CordenPharma brings over 200 combined years of experience in the Small Molecule development and manufacturing market, where we have considerable experience with a repertoire of chemical reactions and transformations, including but not limited to: >> Hydrogenations. >> Oxidations. >> Cryogenics. >> Friedal-Crafts. >> Organometallics.

Get price

Lonza to Expand API Manufacturing Facility - Money Time

Jun 29, 2021  The new mid-scale manufacturing assets at the Nansha site will support the transition of products under development to [] Integrated healthcare solutions supplier Lonza revealed plans Monday to invest CHF 20 million, or about $21.7 million, to expand the API development and manufacturing capabilities at its production site in Nansha, China.

Get price

New production train enters operation at Lonza Visp

Oct 04, 2018  New production train enters operation at Lonza Visp. By Murielle Gonzalez 4-Oct-2018. The high-containment facility is for manufacturing rucaparib, a small molecule inhibitor used as an anti-cancer agent. Clovis Oncology and Lonza have announced the opening of a dedicated production train at Lonza’s Visp site in Switzerland. The new facility ...

Get price

Lonza and Antibody-Drug Conjugates (ADC) on Vimeo

There are many unique challenges in manufacturing highly potent biopharmaceuticals that have encouraged Lonza to design and build a new large-scale manufacturing plant dedicated solely to highly potent production in Visp, Switzerland.

Get price
Contact us

Submit online

Please leave a message below and we will contact you as soon as possible.